APLS Apellis Pharmaceuticals Inc.

-0.02  -0%
Previous Close 18.71
Open 18.62
Price To Book 5.37
Market Cap 1051173652
Shares 56,242,571
Volume 244,452
Short Ratio
Av. Daily Volume 297,482

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
APL-2 subcutaneous
Complement-dependent Nephropathies (CDN)
Phase 2 data presented at ASH 2018.
APL-2 subcutaneous
Auto-immune Hemolytic Anemia (AIHA)
Phase 1b trial ongoing.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 enrollment has temporarily halted due to non-infectious inflammation in patients. Update due 1H December 2018.
Geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Phase 3 trial initiation announced June 26, 2018.
APL-2 subcutaneous
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
Paroxysmal Nocturnal Hemoglobinuria

SEC Filings

  1. D - Notice of Exempt Offering of Securities 10844510